Huadong Medicine Co., Ltd. (hereinafter referred to as "the Company" or "this Company") and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Special Reminder:
- Stage of the litigation (arbitration): The second instance has been accepted and has not yet been heard;
- Position of the listed company: Appellant (first-instance plaintiff);
- Amount involved: 111,386,405 yuan (an increase of 10,600 yuan compared to the initially disclosed provisional amount);
- Impact on the listed company's profits: The second-instance litigation has not yet been heard and does not constitute a significant impact on the company's current or future profits. The company will fulfill its information disclosure obligations in a timely manner based on the progress of the litigation.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongmei Huadong"), a wholly-owned subsidiary of the Company, recently received the "Notice of Acceptance of Appeal Case" (2026) Supreme Court Zhi Xing Zhong 71 and other legal documents delivered by the Supreme People's Court of the People's Republic of China (hereinafter referred to as "the Supreme Court"). The relevant matters are announced as follows: